Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Valter Torri

Showing results (171-180 of 228) with videos related to

Pageof 23
Sort By:
Plos One|August 8, 2019
Neoadjuvant eribulin mesylate following anthracycline and taxane in triple negative breast cancer: Results from the HOPE studySerena Di Cosimo, Nicla La Verde, Anna Moretti, et al.
European Journal of Cancer (Oxford, England : 1990)|November 10, 2023
Systematic review and meta-analysis of immune checkpoint inhibitors as single agent or in combination with chemotherapy in early-stage non-small cell lung cancer: Impact of clinicopathological factors and indirect comparison between treatment strategiesAntonio Nuccio, Giuseppe Viscardi, Fabio Salomone, et al.
Gastric Cancer : Official Journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association|December 29, 2016
Prognostic factors in 868 advanced gastric cancer patients treated with second-line chemotherapy in the real worldValentina Fanotto, Stefano Cordio, Giulia Pasquini, et al.
The Oncologist|April 7, 2019
HER2 Positivity Predicts Unresponsiveness to EGFR-Targeted Treatment in Metastatic Colorectal CancerAndrea Sartore-Bianchi, Alessio Amatu, Luca Porcu, et al.
Cancer Cell|October 22, 2020
Supporting Clinical Decision-Making during the SARS-CoV-2 Pandemic through a Global Research Commitment: The TERAVOLT ExperienceAnnalisa Trama, Claudia Proto, Jennifer G Whisenant, et al.
European Journal of Cancer (Oxford, England : 1990)|November 11, 2023
Association of tumor-infiltrating lymphocytes with recurrence score in hormone receptor-positive/HER2-negative breast cancer: Analysis of four prospective studiesFederica Miglietta, Maria Vittoria Dieci, Tommaso Giarratano, et al.
Frontiers in Immunology|October 7, 2022
Circulating CD81-expressing extracellular vesicles as biomarkers of response for immune-checkpoint inhibitors in advanced NSCLCDiego Signorelli, Patrizia Ghidotti, Claudia Proto, et al.
European Journal of Cancer (Oxford, England : 1990)|April 6, 2021
Poziotinib for EGFR and HER2 exon 20 insertion mutation in advanced NSCLC: Results from the expanded access programArsela Prelaj, Achille Bottiglieri, Claudia Proto, et al.
Tumori|October 10, 2014
Efficacy of trastuzumab in unselected patients with HER2-positive metastatic breast cancer: a retrospective analysisElena Collovà, Antonella Ferzi, Giuseppa Scandurra, et al.
Tumori|February 19, 2024
Nivolumab in pretreated pleural mesothelioma: Results from an observational real-world study of patients treated within the AIFA 5% FundLuigi Cerbone, Sara Delfanti, Stefania Crivellari, et al.
Pageof 23

Showing results (171-180 of 228) with videos related to

Sort By:
Pageof 23
Plos One|August 8, 2019
Neoadjuvant eribulin mesylate following anthracycline and taxane in triple negative breast cancer: Results from the HOPE studySerena Di Cosimo, Nicla La Verde, Anna Moretti, et al.
European Journal of Cancer (Oxford, England : 1990)|November 10, 2023
Systematic review and meta-analysis of immune checkpoint inhibitors as single agent or in combination with chemotherapy in early-stage non-small cell lung cancer: Impact of clinicopathological factors and indirect comparison between treatment strategiesAntonio Nuccio, Giuseppe Viscardi, Fabio Salomone, et al.
Gastric Cancer : Official Journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association|December 29, 2016
Prognostic factors in 868 advanced gastric cancer patients treated with second-line chemotherapy in the real worldValentina Fanotto, Stefano Cordio, Giulia Pasquini, et al.
The Oncologist|April 7, 2019
HER2 Positivity Predicts Unresponsiveness to EGFR-Targeted Treatment in Metastatic Colorectal CancerAndrea Sartore-Bianchi, Alessio Amatu, Luca Porcu, et al.
Cancer Cell|October 22, 2020
Supporting Clinical Decision-Making during the SARS-CoV-2 Pandemic through a Global Research Commitment: The TERAVOLT ExperienceAnnalisa Trama, Claudia Proto, Jennifer G Whisenant, et al.
European Journal of Cancer (Oxford, England : 1990)|November 11, 2023
Association of tumor-infiltrating lymphocytes with recurrence score in hormone receptor-positive/HER2-negative breast cancer: Analysis of four prospective studiesFederica Miglietta, Maria Vittoria Dieci, Tommaso Giarratano, et al.
Frontiers in Immunology|October 7, 2022
Circulating CD81-expressing extracellular vesicles as biomarkers of response for immune-checkpoint inhibitors in advanced NSCLCDiego Signorelli, Patrizia Ghidotti, Claudia Proto, et al.
European Journal of Cancer (Oxford, England : 1990)|April 6, 2021
Poziotinib for EGFR and HER2 exon 20 insertion mutation in advanced NSCLC: Results from the expanded access programArsela Prelaj, Achille Bottiglieri, Claudia Proto, et al.
Tumori|October 10, 2014
Efficacy of trastuzumab in unselected patients with HER2-positive metastatic breast cancer: a retrospective analysisElena Collovà, Antonella Ferzi, Giuseppa Scandurra, et al.
Tumori|February 19, 2024
Nivolumab in pretreated pleural mesothelioma: Results from an observational real-world study of patients treated within the AIFA 5% FundLuigi Cerbone, Sara Delfanti, Stefania Crivellari, et al.
Pageof 23